Skip to main
FTH

FTH Stock Forecast & Price Target

FTH Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Faeth Therapeutics is positioned to be a major player in the biotechnology industry due to their focus on critical oncogenic pathways and strong pipeline of drugs in development, such as the PIKTOR regimen for breast and endometrial cancer. With a promising target price and various partnerships and ongoing studies, the company has the potential for significant growth and impact in the field of cancer research and treatment. Despite potential risks and challenges, the combination of PAM inhibition, endocrine therapy, and CDK4/6 inhibition could prove to be a successful treatment approach and generate positive financial returns for shareholders in the long term.

Bears say

Faeth Therapeutics is facing significant competition in the PI3K inhibitor market, with established companies and new players entering the space with promising treatments. Moreover, the success of other treatments in the market may hinder the potential success of Faeth's PIKTOR treatment. Additionally, the lack of previous clinical data and the relatively early stages of development for PIKTOR may raise concerns about its efficacy and potential side effects.

FTH has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sensei Biotherapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sensei Biotherapeutics Inc (FTH) Forecast

Analysts have given FTH a Buy based on their latest research and market trends.

According to 8 analysts, FTH has a Buy consensus rating as of Sep 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $56.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $56.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sensei Biotherapeutics Inc (FTH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.